KR880013559A - 플루나리진 함유 약제조성물 - Google Patents

플루나리진 함유 약제조성물 Download PDF

Info

Publication number
KR880013559A
KR880013559A KR1019880005737A KR880005737A KR880013559A KR 880013559 A KR880013559 A KR 880013559A KR 1019880005737 A KR1019880005737 A KR 1019880005737A KR 880005737 A KR880005737 A KR 880005737A KR 880013559 A KR880013559 A KR 880013559A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
carrier
composition according
castor oil
active ingredient
Prior art date
Application number
KR1019880005737A
Other languages
English (en)
Inventor
머센즈 쟌
폴 반 페에르 아시엘
쟌 피에테르 헤이칸트스 죠제프
Original Assignee
폴 아드리안 쟌 쟈안센
쟈안센 파아마슈우티카 엔.부이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴 아드리안 쟌 쟈안센, 쟈안센 파아마슈우티카 엔.부이 filed Critical 폴 아드리안 쟌 쟈안센
Publication of KR880013559A publication Critical patent/KR880013559A/ko

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fertilizers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

내용 없음

Description

플루나리진 함유 약제조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (16)

  1. 유효성분으로 일반식(Ⅰ)의 화합물, 그 산부가염 또는 그 입체화학이성체를 함유하고 담체로 1이상의 계면활성제나 시클로덱스트린 또는 그 유도체와 임의로 1이상의 보조제로 조성된 약제조성물.
  2. 제1항에 있어서, 담체가 계면활성제인 약제조성물.
  3. 제2항에 있어서, 담체가 비이온성 계면활성제인 약제조성물.
  4. 제3항에 있어서, 계면활성제가 폴리에톡시화지방산, 알콜이나, 폴리에톡시화기름 또는 지방인 약제 조성물.
  5. 제3항에 있어서 담체가 1몰의 피마자기름과 100몰의 산화에틸렌의 반응물질인 폴리에톡시화피마자 기름 또는 수소화피마자기름인 약제조성물.
  6. 제5항에 있어서, 담체가 1몰의 피마자기름과 30내지 50몰의 산화에틸렌의 반응물질인 폴리에톡시화피마자기름 또는 수소화피마자기름인 약제조성물.
  7. 제6항에 있어서, 담체가 1몰의 피마자기름과 40몰의 산화에틸렌의 반응물질인 약제조성물.
  8. 제1항 내지 제7항의 어느 한 항에 있어서, 담체를 50%이상 함유하는 약제조성물.
  9. 제1항 내지 제7항의 어느 한 항에 있어서, 담체를 80%이상 함유하는 약제조성물.
  10. 제1항 내지 제9항의 어느 한 항에 있어서, 포장수단이 경질 제랄틴캡슐인 약제조성물.
  11. 제10항에 있어서, 0.1내지 5중량%의 물과 임의로 0.1내지 3중량%의 수산화나트륨을 함유하는 약제조성물.
  12. 알레르기성질환, 뇌 및/또는 주변혈관부전증, 현운 및 동요병등에 감염한 온혈동물에 상기 제1항 내지 제11항의 약제조성물을 투여하여 감염질환을 치료하는 방법.
  13. 유효성분을 담체 및 그밖의 보조제와 고루 혼합하여 제1항 내지 제9항의 약제조성물의 제조하는 방법.
  14. 각 성분을 담체의 융점 또는 약화점(weaking point)이상의 온도에서 고루 혼합하여, 제2항 내지 제11항의 약제조성물을 제조하는 방법.
  15. 제14항에 있어서, 유효성분을 보온용기중, 45℃내지 50℃에서 혼합하여 약제조성물을 제조하는 방법.
  16. 유효성분을 고루 혼합한후, 경질 젤라틴캡슐에 충전하는 제10항 또는 제11항의 약제조성물을 제조하는 방법.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019880005737A 1987-05-18 1988-05-17 플루나리진 함유 약제조성물 KR880013559A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5064487A 1987-05-18 1987-05-18
US050,644 1987-05-18

Publications (1)

Publication Number Publication Date
KR880013559A true KR880013559A (ko) 1988-12-21

Family

ID=21966482

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880005737A KR880013559A (ko) 1987-05-18 1988-05-17 플루나리진 함유 약제조성물

Country Status (19)

Country Link
EP (1) EP0292050B1 (ko)
JP (1) JPS63303926A (ko)
KR (1) KR880013559A (ko)
AT (1) ATE69555T1 (ko)
AU (1) AU603895B2 (ko)
DE (1) DE3866281D1 (ko)
DK (1) DK268788A (ko)
ES (1) ES2051827T3 (ko)
FI (1) FI882307A (ko)
GR (1) GR3003482T3 (ko)
HU (1) HU199073B (ko)
IE (1) IE60937B1 (ko)
IL (1) IL86395A (ko)
NO (1) NO882134L (ko)
NZ (1) NZ224497A (ko)
PH (1) PH24425A (ko)
PT (1) PT87496B (ko)
RU (1) RU1829935C (ko)
ZA (1) ZA883492B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532002A (en) * 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
EP0487575B1 (en) * 1989-08-17 1994-11-02 Cortecs Limited Pharmaceutical formulations
KR100371062B1 (ko) * 1992-11-27 2003-04-21 에프.에이치.포울딩 앤드 컴퍼니 리미티드 안정성이향상된주사가능한택솔조성물및이를제형화하는방법
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
FR2729307B1 (fr) * 1995-01-18 1997-04-18 Seppic Sa Utilisation d'esters d'acides gras ethoxyles comme composants auto-emulsionnables notamment utiles pour la preparation de produits de traitement phytosanitaires ou de medicaments a usage veterinaire ou humain
KR20010031520A (ko) * 1997-11-07 2001-04-16 스즈키 다다시 피페라진류-시클로덱스트린 복합체
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
HU229505B1 (hu) * 2001-09-10 2014-01-28 Tibotec Pharm Ltd Eljárás hexahidrofuro [2,3-b]furán-3-ol elõállítására
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
EP2488022B1 (en) 2009-10-16 2018-01-10 Mochida Pharmaceutical Co., Ltd. Compositions
CN104069086A (zh) * 2014-07-22 2014-10-01 周有财 一种盐酸氟桂利嗪组合物胶囊及其制备方法
CN113262207B (zh) * 2020-02-17 2022-06-17 正大青春宝药业有限公司 一种盐酸氟桂利嗪胶囊制剂及其制备方法
CN115381791B (zh) * 2022-09-21 2023-06-16 迪沙药业集团有限公司 一种盐酸氟桂利嗪药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3582935D1 (de) * 1984-01-28 1991-07-04 Roshdy Ismail Mittel zur behandlung von erkrankungen der venen und des analbereichs.
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US5047229A (en) * 1986-12-17 1991-09-10 Miles, Inc. Treatment of cardiovascular and cerebral toxicity using calcium modulators

Also Published As

Publication number Publication date
PH24425A (en) 1990-06-25
EP0292050B1 (en) 1991-11-21
NO882134L (no) 1988-11-21
NO882134D0 (no) 1988-05-16
EP0292050A1 (en) 1988-11-23
ZA883492B (en) 1990-01-31
DK268788A (da) 1988-11-19
RU1829935C (ru) 1993-07-23
IE60937B1 (en) 1994-09-07
IL86395A0 (en) 1988-11-15
AU1613288A (en) 1988-11-24
ES2051827T3 (es) 1994-07-01
IL86395A (en) 1992-11-15
HUT46851A (en) 1988-12-28
JPS63303926A (ja) 1988-12-12
PT87496A (pt) 1989-05-31
NZ224497A (en) 1990-04-26
AU603895B2 (en) 1990-11-29
PT87496B (pt) 1992-09-30
FI882307A (fi) 1988-11-19
FI882307A0 (fi) 1988-05-17
DK268788D0 (da) 1988-05-17
DE3866281D1 (de) 1992-01-02
GR3003482T3 (en) 1993-02-17
HU199073B (en) 1990-01-29
IE881477L (en) 1988-11-18
ATE69555T1 (de) 1991-12-15

Similar Documents

Publication Publication Date Title
KR880013559A (ko) 플루나리진 함유 약제조성물
KR890008155A (ko) 신규인 유도체, 그 제조방법 및 의약에서의 사용
KR970702291A (ko) 에퀼린의 산 이성질화체로부터 제조된 에퀼린 이중결합 이성질체(Anequilin double bond isomer from the acid isomerization of equilin)
ATE2622T1 (de) 2-niedrigalkyl-7-substituierte-2 oder 3-cephem-4- carbonsaeuren, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ES2043891T3 (es) Procedimiento para preparar nuevos agentes antiarritmicos ii.
PT82512A (fr) Procede de preparation de derives de quinolylglycinamides ayant activite psychotrope et de compositions pharmaceutiques les contenant
GB1353635A (en) Coating composition for moist surfaces
GB965301A (en) Novel ethers and a process for their manufacture
GB1015787A (en) Tris-(p-methoxyphenyl)ethylene derivatives
DE2962917D1 (en) Aminopropanol derivatives of 6-hydroxy-2,3,4,5-tetrahydro-1h-1-benzazepin-2-ones, process for their preparation, and pharmaceutical compositions containing them
GB1112334A (en) Improvements in or relating to isoquinolo[2,1-d]benzo[1,4]diazepine derivatives
ATE34739T1 (de) Neue 2-pyridin-thiol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
US2332075A (en) Epinephrine derivative and preparation thereof
GB2001974A (en) Vincinic acid derivatives and process for the preparation thereof
KR880001652A (ko) 이소퀴놀린 유도체 및 이의 제조 방법
DE3466390D1 (en) Cyclic dithioacetamides, process for their preparation and pharmaceutical compositions containing them
ATE965T1 (de) Aminopropanolderivate des 2-(o-hydroxyphenyl)-pyrrols, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
JPH02138118A (ja) シクロペンテノン類を活性成分とする骨形成促進剤
US2726984A (en) Composition for combatting amoebiasis comprising 1:2-bis(4'-arsono-phenylamino)-ethane
DE3460079D1 (en) Substituted thioamides of hydroxy-malonic acids, process for their preparation and their use as pesticides
SE8401748L (sv) Antimykotiskt medel i form av krem med hoggradig frigoring av verksam substans
KR910002789A (ko) 아크릴산염, 이것의 제조방법, 이것을 함유한 제약조성물 및 의약에서 이것을 사용하는 방법
KR890005123A (ko) 세펨 화합물 및 이의 제조방법
GB746051A (en) S:s-diethyldithioterephthalate and therapeutic compositions containing the same
KR890017228A (ko) 부정맥치료제

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application